Forgot your password?

Forgot your username?

database > company
Synthetic Biologics, Inc.
HCID Member | Biotech Specialty Pharma
3985 Research Park Dr., Ste. 200
Ann Arbor, MI 48108 USA
phone:(734) 332-7800
fax:(734) 332-7878
Symbol SYN
Exchange NYSE Amex
Founded 2001
Employees 8
www.syntheticbiologics.com
Research Sector Biotech Specialty Pharma
Summary Description
Focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Developing, or partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).
Management
- Jeffrey Riley, CEO, President and Director; - C. Evan Ballantyne, CFO; - Carol Reed, MD, Senior Vice President of Clinical & Regulatory Affairs; - John Monahan, PhD, Senior Vice President of Research & Development;
Ownership
Financials Mkt Cap :53
* numbers in thousands
 

Keywords
synthetic biologics, DNA-based therapeutics, multiple sclerosis, cognitive dysfunction, pulmonary arterial hypertension, amyotrophic lateral lateral sclerosis, ALS, Lou Gehrig's disease, zinc

Comment | Printable Version | Modify profile |
Updated: May 23, 2012

Description
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).
Products / Services
1-Relapsing-remitting multiple sclerosis (MS) - Trimesta (oral estriol) - (Status: Phase II clinical trial fully enrolled) 2-Cognitive dysfunction in MS - Trimesta (oral estriol) - (Status: Phase II clinical trial enrolling) 3-Fibromyalgia - Effirma (oral flupirtine) - (Status: partnered with Meda AB in 2010) 4-Lou Gehrig's disease - AEN-100 (gastroretentive zinc acetate) - (Status: preparing for Phase II/III clinical trial) 5-Pulmonary arterial disease - Synthetic DNA-based therapy - (Status: Preclinical)